Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: Effect of corticosteroids, methotrexate and azathioprine

Arthritis Research and Therapy

Volumn 14, Issue 1, 2012, Pages

  Schiopu, Elena ^a   Phillips, Kristine ^a   MacDonald, Paul M ^b   Crofford, Leslie J ^c   Somers, Emily C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; ARTICLE; CAUCASIAN; CAUSE OF DEATH; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYMYOSITIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; COHORT ANALYSIS; INTRAVENOUS ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS; TIME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; AZATHIOPRINE; COHORT STUDIES; DERMATOMYOSITIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); POLYMYOSITIS; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS;

EID: 84856153535     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3704     Document Type: Article

References (29)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982. 10.1016/S0140-6736(03)14368-1, 14511932.
2. Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008, 59:677-685. 10.1002/art.23571, 18438901.
3. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84:223-243. 10.1006/clin.1997.4412, 9281381.
4. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009, 33:197-207. 10.1016/j.jaut.2009.09.008, 2783422, 19819109.
5. Medsger TA, Robinson H, Masi AT. Factors affecting survivorship in polymyositis: a life-table study of 124 patients. Arthritis Rheum 1971, 14:249-258. 10.1002/art.1780140210, 5549971.
6. Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986, 15:168-178. 10.1016/0049-0172(86)90014-4, 3515559.
7. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996, 14:263-274.
8. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006, 25:234-239. 10.1007/s10067-005-1164-z, 16477398.
9. Choy EH, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005, 3:CD003643.
10. World Health Organization ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification Geneva: World Health Organization, World Health Organization.
11. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347. 10.1056/NEJM197502132920706, 1090839.
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403-407. 10.1056/NEJM197502202920807, 1089199.
13. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 2002, 41:22-26.
14. Kaplan MJ. Endothelial damage and autoimmune diseases. Autoimmunity 2009, 42:561-562. 10.1080/08916930903002453, 19863374.
15. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Shelden E, McCune WJ, Kaplan MJ. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004, 103:3677-3683. 10.1182/blood-2003-09-3198, 14726373.
16. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007, 110:2907-2915. 10.1182/blood-2007-05-089086, 2018671, 17638846.
17. Lundberg IE, Forbess CJ. Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 2008, 26(5 Suppl 51):S109-S114.
18. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004, 50:3408-3417. 10.1002/art.20583, 15529366.
19. Spies CM, Bijlsma JW, Burmester GR, Buttgereit F. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol 2010, 10:302-307. 10.1016/j.coph.2010.02.001, 20202903.
20. Winkelmann RK, Mulder DW, Lambert EH, Howard FM, Diessner GR. Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients. Mayo Clin Proc 1968, 43:545-556.
21. Carpenter JR, Bunch TW, Engel AG, O'Brien PC. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol 1977, 4:207-214.
22. O''Hanlon TP, Rider LG, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 2006, 54:3670-3681. 10.1002/art.22205, 17075818.
23. Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974, 81:182-189.
24. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980, 92:365-369.
25. Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981, 24:45-48. 10.1002/art.1780240107, 7008799.
26. Miller J, Walsh Y, Saminaden S, Lecky BRF, Winer JB. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy [abstract]. J Neurol Sci 2002, 199:S53.
27. Joffe MM, Love LA, Leff RL, Fraser D, Targoff IN, Hicks JE, Plotz PH, Miller FW. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:379-387. 10.1016/0002-9343(93)90148-I, 8386437.
28. Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW, Adams EM, Ballinger SH, Bowyer SL, Gomez O, Harris-Love MO, Jain MS, Joe GO, Hill S, James-Newton L, Lindsley CB, Passo MH, Perez MD, Plotz PH, Wallace CA, Zemel LS, . International Myositis Assessment and Clinical Studies (IMACS) Group Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009, 60:3425-3435. 10.1002/art.24904, 2793533, 19877055, International Myositis Assessment and Clinical Studies (IMACS) Group.
29. Somers EC, Marder W, Lewis EE, Francis S, Cagnoli PC, DeGuire P, Gordon C, Helmick CG, Leisen JC, Dhar JP, McCune WJ, . MILES Group Michigan Lupus Epidemiology & Surveillance Program (MILES): increased proportion of target-organ threatening involvement among male versus female SLE patients [abstract]. Arthritis Rheum 2009, 60(Suppl 10):302. MILES Group.